PPT-New IDSA/AASLD Guidelines for Hepatitis C

Author : debby-jeon | Published Date : 2016-07-01

John Scott MD MSc Associate Professor UW SoM Asst Director Liver Clinic Harborview Medical Center Presentation prepared by Maggie Shuhart MD and John Scott MD

Presentation Embed Code

Download Presentation

Download Presentation The PPT/PDF document "New IDSA/AASLD Guidelines for Hepatitis ..." is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.

New IDSA/AASLD Guidelines for Hepatitis C: Transcript


John Scott MD MSc Associate Professor UW SoM Asst Director Liver Clinic Harborview Medical Center Presentation prepared by Maggie Shuhart MD and John Scott MD Last Updated Dec 3 2014. Hepatitis A formerly called infectious hepatitis and hepatitis B formerly called serum hepatitis have been recognized as separate entities since the early 1940s and can be diagnosed with specific serologic tests Delta hepatitis is an infection depen Nicolle Suzanne Bradley Richard Colgan James C Rice Anthony Schaeffer and Thomas M Hooton University of Manitoba Winnipeg Canada University of Michigan Ann Arbor University of Maryland Baltimore University of Texas Galveston Northwestern University Tunkel Carol A Glaser Karen C Bloch James J Sejvar Christina M Marra Karen L Roos Barry J Hartman Sheldon L Kaplan W Michael Scheld and Richard J Whitley 10 Monmouth Medical Center Long Branch New Jersey California Department of Health Services Rich 1 Defence Offset Guidelines - ALanguorous Journey So Far Amit Cowshish Amit Cowshish is a former Financial Advisor (Acquisition) & Additional August 5, 2013 IDSIDSIDSIDSIDSA ISSUE BRIEFA ISSUE BRIEF Eleana. M. Zamora, MD. Department of Internal Medicine. Division of Pulmonary/Critical Care/Sleep. Objectives. Understand the difference between . nosocomial. and community-acquired. Know where to find . This program is s. upported. by educational grants from AbbVie; Gilead Sciences; Janssen Therapeutics; Merck & Co., Inc; and . ViiV. Healthcare. . About These Slides. Please feel free to use, update, and share some or all of these slides in your noncommercial presentations to colleagues or patients. Gottfried . Hirnschall. Background . HCV infection significant cause of morbidity and mortality:. 130–150 million persons with chronic HCV infection. 350,000–500,000 annual deaths. Rapidly changing therapeutic environment. Medical Director, Austin Hepatitis Center. 1. Hepatitis C & PCP’s. 2. LACK OF AWARENESS. LACK OF APPROPRIATE ACTION. Expand Quantitative Landscape Study – Oct 2013 [Gilead Sciences]. 35-50% of PCP believe HCV can be cured. Slides for today’s webinar are available on the CIHS website at: http://www.integration.samhsa.gov/mai-coc-grantees-online-community/webinars How to ask a question during the webinar If you are listening to this webinar from your computer speakers, please type your questions into the question box and we will address your questions. 2017 VERSION 2TROPICAL AND INFECTIOUS DISEASES UNIT ROYAL LIVERPOOL UNIVERSITY HOSPITALTropical and Infectious Diseases UnitRoyal Liverpool University HospitalClinical Guidelines2017 Version 2Lead Edi Condition. National Notification Criteria*. Print Criteria†. Hepatitis. . A. Confirmed. Confirmed. Acute . hepatitis. . B. Confirmed. Confirmed. Chronic . hepatitis. . B. Confirmed. . and. . probable. About these slides. These slides give a comprehensive overview of the EASL clinical practice guidelines on . the management of hepatitis E infection. The guidelines were first presented at the International Liver Congress 2018 and will be published soon in . This one-hour presentation supports the instruction of . comprehensive cancer control professionals and stakeholders during program or coalition meetings . to 1) describe the connection between chronic hepatitis B and C viruses and liver cancer and at-risk populations; 2) list strategies outlined in the landmark National Academies of Sciences, Engineering and Medicine’s (NASEM) “A National Strategy for the Elimination of Hepatitis B and C: Phase Two Report” to reduce new cases of liver cancer; and 3) locate resources and partner organizations to introduce or improve strategies to eliminate hepatitis B and C viruses and reduce new cases of liver cancer in our community.. WHO Global HIV Hepatitis and STI Programmes. 18 July 2021. WHO’s goal is to eliminate viral hepatitis as a major public health problem by 2030. . 6-10 million infections (in 2015) . to 900,000 infections (by 2030).

Download Document

Here is the link to download the presentation.
"New IDSA/AASLD Guidelines for Hepatitis C"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.

Related Documents